← Revolution Medicines overview

Revolution Medicines vs Regeneron Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Revolution Medicines Inc (RVMD)

Q3 2026
▲3▼1

FDA approval turns Revolution Medicines into commercial-stage company

  • Daraxonrasib Phase 3 survival win Strong Phase 3 data for daraxonrasib in metastatic pancreatic cancer nearly doubled median overall survival, a major clinical win that supports a roughly $40 billion valuation and validates the company's RAS-targeted approach.

    This was the key clinical catalyst that re-rated the stock during the quarter.

  • FDA approval of Rasonque In September the FDA approved daraxonrasib (Rasonque), the first RAS-targeted pancreatic cancer drug, making Revolution Medicines a commercial-stage company with real revenue potential and a first-mover position.

    The approval is the single biggest new event, changing the company's business model.

  • Regulatory designations and funding Breakthrough Therapy and Orphan Drug designations, EMA accelerated review, and a Royalty Pharma deal fund the pipeline without dilution, while Parnassus Growth Equity initiated a position, signaling institutional confidence.

    These developments de-risk the launch and strengthen the balance sheet without shareholder dilution.

  • Cost and pricing concerns A wider-than-expected Q2 loss and raised 2026 spending guidance (second time) cast doubt on profitability timing, while Rasonque's $39,800 monthly price raises insurer coverage and patient affordability concerns that could limit sales.

    This is the main counterweight, showing the commercial path is not without financial and access risks.

September 2026
▲3

FDA approval turns Revolution Medicines into a commercial cancer drugmaker

  • FDA approves first RAS-targeted pancreatic cancer drug The FDA approved daraxonrasib, sold as Rasonque, for previously treated metastatic pancreatic cancer. It is the first targeted pill for this hard-to-treat disease, nearly doubling median survival versus chemotherapy. This turns a clinical-stage company into one with an approved product and real revenue potential, lifting the stock.

    This is the single biggest new event of the period and the core reason RVMD is moving.

  • Price set at $39,800 per month Revolution priced Rasonque at $39,800 for a 30-day supply, about $477,600 a year before discounts. That is high enough to raise concerns about whether insurers will cover it and whether patients can afford it, which could limit sales even though the price itself supports revenue per patient.

    Pricing is the main commercial counterweight to the approval and directly affects how much revenue the drug can generate.

  • Royalty Pharma deal funds pipeline without dilution A new partnership with Royalty Pharma provides funding for Revolution's pipeline without selling more shares. That matters because the company had no revenue in FY2025 and lost about $1.1 billion, so this eases the need for cash and protects existing shareholders from dilution.

    It answers how the company pays for its pipeline now that it has a product but still spends heavily.

  • Fund manager cites drug as potential new standard of care Parnassus Growth Equity Fund added Revolution Medicines as a new holding, saying daraxonrasib's late-stage results suggest it could become a standard treatment for pancreatic cancer with significant commercial potential. A respected fund buying in signals growing institutional confidence, which can support the stock.

    It shows professional investors are treating the approval as a durable long-term opportunity, not just a one-day event.

Latest
▲3

FDA approval turns Revolution Medicines into a commercial cancer drugmaker

  • FDA approves first RAS-targeted pancreatic cancer drug The FDA approved daraxonrasib, sold as Rasonque, for previously treated metastatic pancreatic cancer. It is the first targeted pill for this hard-to-treat disease, nearly doubling median survival versus chemotherapy. This turns a clinical-stage company into one with an approved product and real revenue potential, lifting the stock.

    This is the single biggest new event of the period and the core reason RVMD is moving.

  • Price set at $39,800 per month Revolution priced Rasonque at $39,800 for a 30-day supply, about $477,600 a year before discounts. That is high enough to raise concerns about whether insurers will cover it and whether patients can afford it, which could limit sales even though the price itself supports revenue per patient.

    Pricing is the main commercial counterweight to the approval and directly affects how much revenue the drug can generate.

  • Royalty Pharma deal funds pipeline without dilution A new partnership with Royalty Pharma provides funding for Revolution's pipeline without selling more shares. That matters because the company had no revenue in FY2025 and lost about $1.1 billion, so this eases the need for cash and protects existing shareholders from dilution.

    It answers how the company pays for its pipeline now that it has a product but still spends heavily.

  • Fund manager cites drug as potential new standard of care Parnassus Growth Equity Fund added Revolution Medicines as a new holding, saying daraxonrasib's late-stage results suggest it could become a standard treatment for pancreatic cancer with significant commercial potential. A respected fund buying in signals growing institutional confidence, which can support the stock.

    It shows professional investors are treating the approval as a durable long-term opportunity, not just a one-day event.

July 2026
▲3▼1

RVMD Soars on Strong Phase 3 Data, Regulatory Wins, and Competitive Edge

  • Daraxonrasib Phase 3 Data Revolution Medicines reported strong Phase 3 results for daraxonrasib in metastatic pancreatic cancer, with median overall survival nearly doubling to 13.2 months from 6.7 months, supporting a ~$40B valuation and a $10B+ market opportunity.

    This is the primary positive catalyst that drove the stock's surge during the period.

  • Regulatory Designations and NDA Acceptance The company received Breakthrough Therapy and Orphan Drug designations, EMA accelerated review, and FDA acceptance of the daraxonrasib NDA with a fast-review voucher, building regulatory momentum.

    These regulatory milestones accelerate the path to market and boost investor confidence.

  • Competitor Erasca Legal Woes Erasca faces securities litigation and investigations over alleged misleading comparisons to RVMD's RMC-6236, erasing $2.8B in market cap, which strengthens RVMD's competitive position.

    This weakens a rival and reinforces RVMD's leadership in the RAS cancer space.

  • Wider Q2 Loss and Raised Spending Guidance RVMD reported a wider-than-expected Q2 loss and raised 2026 spending guidance for the second time, raising doubts about how soon the company can reach profitability.

    This is a counterweight that could pressure the stock despite positive pipeline news.

▲3▼1

FDA accepts daraxonrasib NDA, but rising costs test RVMD's valuation

  • FDA accepts daraxonrasib NDA The FDA accepted Revolution Medicines' application for daraxonrasib in metastatic pancreatic cancer, a key step toward approval. The drug also got a fast-review voucher. This raises the chance of a launch and future sales, supporting the stock.

    This is the period's biggest new regulatory event and directly drives RVMD's potential revenue.

  • Druckenmiller's fund buys RVMD shares Billionaire Stanley Druckenmiller's family office bought 316,000 shares. A well-known investor buying in can boost confidence and attract other buyers, pushing the stock up. It also highlights the drug's strong survival data.

    This is a new, specific event that can influence investor sentiment and demand for the stock.

  • Wider Q2 loss and higher expense guidance Revolution Medicines reported a bigger quarterly loss than expected and raised its 2026 spending forecast for the second time. Costs are climbing fast as it prepares for launch. This raises doubts about how soon it can become profitable, weighing on the stock.

    This is the main new negative financial update and a real counterweight to the positive news.

  • Erasca legal probe continues Hagens Berman is investigating Erasca over alleged misleading claims about its drug, including flawed comparisons to RVMD's RMC-6236. This keeps pressure on a competitor and reinforces RVMD's competitive edge in RAS cancer drugs.

    It is a new development in a competitive threat that benefits RVMD's relative position.

▲4

Revolution Medicines' cancer data and regulatory wins drive RVMD higher

  • Daraxonrasib Phase 3 survival data and $40B valuation Daraxonrasib nearly doubled median overall survival (13.2 vs 6.7 months) in previously treated metastatic pancreatic cancer, supporting a potential $10B+ opportunity and a ~$40B market value. This validates the pipeline and raises expectations for future revenue.

    This is the core clinical catalyst that justifies RVMD's valuation and future revenue potential.

  • Zoldonrasib combination shows high response rates Phase 1/2 data for zoldonrasib plus chemo in RAS G12D pancreatic cancer showed 82% and 61% response rates in untreated patients, and 50% in previously treated patients. These results support ongoing Phase 3 trials and expand the pipeline's potential.

    New positive data for a second drug candidate broadens the growth story and de-risks the pipeline.

  • Regulatory progress: Breakthrough Therapy, Orphan Drug, EMA accelerated review Daraxonrasib received Breakthrough Therapy and Orphan Drug designations, and the European Medicines Agency launched an accelerated review. The company is nearing completion of its New Drug Application to the FDA, setting the stage for a potential global launch.

    Regulatory milestones shorten the path to market and increase the probability of approval, directly impacting future sales.

  • Erasca legal troubles weaken a competitor Erasca faces a securities class action over alleged improper comparisons to RVMD's RMC-6236 and a patient death, erasing $2.8B in market cap. This strengthens RVMD's competitive position and intellectual property standing in the RAS cancer space.

    A weakened competitor reduces competitive pressure and reinforces RVMD's leadership, supporting its pricing power and market share.

Q2 2026
▲3

Revolution Medicines advances pancreatic cancer pipeline as rival Erasca faces legal fallout

  • Phase 3 trial launch for zoldonrasib Revolution Medicines began treating patients in RASolute 305, a Phase 3 trial of zoldonrasib plus chemotherapy for first-line metastatic pancreatic cancer. This is a key step toward a potential new drug, boosting investor confidence in the company's pipeline and future revenue.

    This is a major clinical milestone that directly advances RVMD's lead drug and could drive long-term value.

  • Upcoming data presentations at ESMO GI 2026 Revolution Medicines will present clinical data from its RAS(ON) inhibitor pipeline at the ESMO GI 2026 congress, including oral reports on zoldonrasib combinations and updates on two Phase 3 trials. Positive data could further validate the pipeline and attract investor interest.

    Upcoming data readouts are near-term catalysts that can influence RVMD's stock price.

  • Competitive edge from Erasca patent dispute Revolution Medicines accused rival Erasca of patent infringement and trade secret misappropriation over ERAS-0015, leading to a securities class action against Erasca. This weakens a competitor and reinforces RVMD's intellectual property position in the RAS cancer space.

    The legal challenge against Erasca strengthens RVMD's competitive standing and removes a potential rival.

June 2026
▲3

Revolution Medicines advances pancreatic cancer pipeline as rival Erasca faces legal fallout

  • Phase 3 trial launch for zoldonrasib Revolution Medicines began treating patients in RASolute 305, a Phase 3 trial of zoldonrasib plus chemotherapy for first-line metastatic pancreatic cancer. This is a key step toward a potential new drug, boosting investor confidence in the company's pipeline and future revenue.

    This is a major clinical milestone that directly advances RVMD's lead drug and could drive long-term value.

  • Upcoming data presentations at ESMO GI 2026 Revolution Medicines will present clinical data from its RAS(ON) inhibitor pipeline at the ESMO GI 2026 congress, including oral reports on zoldonrasib combinations and updates on two Phase 3 trials. Positive data could further validate the pipeline and attract investor interest.

    Upcoming data readouts are near-term catalysts that can influence RVMD's stock price.

  • Competitive edge from Erasca patent dispute Revolution Medicines accused rival Erasca of patent infringement and trade secret misappropriation over ERAS-0015, leading to a securities class action against Erasca. This weakens a competitor and reinforces RVMD's intellectual property position in the RAS cancer space.

    The legal challenge against Erasca strengthens RVMD's competitive standing and removes a potential rival.

▲3

Revolution Medicines advances pancreatic cancer pipeline as rival Erasca faces legal fallout

  • Phase 3 trial launch for zoldonrasib Revolution Medicines began treating patients in RASolute 305, a Phase 3 trial of zoldonrasib plus chemotherapy for first-line metastatic pancreatic cancer. This is a key step toward a potential new drug, boosting investor confidence in the company's pipeline and future revenue.

    This is a major clinical milestone that directly advances RVMD's lead drug and could drive long-term value.

  • Upcoming data presentations at ESMO GI 2026 Revolution Medicines will present clinical data from its RAS(ON) inhibitor pipeline at the ESMO GI 2026 congress, including oral reports on zoldonrasib combinations and updates on two Phase 3 trials. Positive data could further validate the pipeline and attract investor interest.

    Upcoming data readouts are near-term catalysts that can influence RVMD's stock price.

  • Competitive edge from Erasca patent dispute Revolution Medicines accused rival Erasca of patent infringement and trade secret misappropriation over ERAS-0015, leading to a securities class action against Erasca. This weakens a competitor and reinforces RVMD's intellectual property position in the RAS cancer space.

    The legal challenge against Erasca strengthens RVMD's competitive standing and removes a potential rival.

Regeneron Pharmaceuticals Inc (REGN)

Q3 2026
▲2▼2

Regeneron's Q3: pipeline wins, Sanofi deal, but melanoma setback

  • Strong Q2 results and pipeline progress Regeneron reported Q2 revenue up 17% to $4.29 billion, received FDA priority review for cemdisiran in myasthenia gravis, and won approval for Pasatru in FOP disease. These advances support future growth.

    These positive developments drove investor optimism and supported the stock.

  • Expanded Sanofi deal and obesity drug data Regeneron expanded its Sanofi partnership with $1 billion upfront and four pipeline therapies. Its obesity drug trevogrumab preserved about 70% of muscle loss in a Phase 2 trial, showing promise in a large market.

    The deal and trial data are new positive catalysts for Regeneron's growth outlook.

  • Failed melanoma trial and lawsuits A failed melanoma trial led to class-action lawsuits and an $11 billion market-value loss. This setback raised concerns about pipeline execution and weighed on the stock.

    This was a major negative event that hurt investor confidence and the share price.

  • Eylea competition and Sanofi deal disappointment Eylea faces biosimilar and competitive threats, notably Kodiak's less-frequent-dosing eye drug. The Sanofi deal left Dupixent profit-sharing unchanged, disappointing some investors and briefly pressuring shares.

    These competitive and deal-related concerns created headwinds for the stock.

August 2026
▲2▼1

Regeneron's strong Q2 and pipeline wins offset by legal and competitive risks

  • Strong Q2 earnings and margin improvement Regeneron beat Q2 estimates with revenue up 17% to $4.29 billion, driven by Dupixent and high-dose Eylea. Repaying the Sanofi Development Balance should improve margins, and buybacks and dividends support shareholder value.

    This point explains the positive financial performance that drove the stock during the period.

  • Pipeline progress and new Sanofi deal FDA approval of Pasatru for rare FOP disease validates Regeneron's drug platform. A new Sanofi deal adds $1 billion upfront and four pipeline therapies, strengthening the pipeline and providing external validation.

    This point highlights key pipeline and partnership developments that boosted investor sentiment.

  • Pipeline uncertainty and Eylea competition Mixed melanoma trial results and increasing competition for Eylea add pipeline uncertainty. These factors offset strong commercial performance and contribute to a balanced but cautious outlook.

    This point explains the competitive and pipeline challenges that acted as a counterweight to positive developments.

Latest
▲2▼2

Regeneron's Sanofi deal and pipeline progress offset by Eylea competition and lawsuits

  • Sanofi deal expands pipeline with $1B upfront Regeneron and Sanofi agreed to jointly develop four long-acting immunology therapies, led by REGN20423, in a deal worth up to $8 billion including $1 billion upfront. This brings cash and pipeline growth, supporting future revenue and the stock.

    This is a major new partnership that directly boosts Regeneron's pipeline and cash, a key positive driver.

  • Securities class action lawsuits weigh on sentiment Multiple law firms filed class actions alleging Regeneron made false statements about its Fianlimab-Libtayo trial, causing investor losses. The legal uncertainty and potential reputational damage pressure the stock, though the company denies wrongdoing.

    These lawsuits are a new negative overhang that could affect investor confidence and lead to financial penalties.

  • Mixed melanoma trial results lead to pullback Regeneron's melanoma drug trial produced mixed results, causing shares to give back some gains. This setback raises doubts about the drug's potential and adds to pipeline uncertainty, weighing on the stock.

    This is a new clinical setback that directly impacts Regeneron's oncology pipeline and investor expectations.

  • Buybacks and dividend support shareholder value Regeneron confirmed its quarterly dividend, updated on share repurchases, and reported Q2 results. With the stock trading below fair value estimates, these capital returns and pipeline progress support the shares.

    This shows management's commitment to returning cash and the stock's valuation appeal, a positive for investors.

September 2026
▲3▼1

Regeneron's pipeline wins and Sanofi deal offset by Eylea competition

  • Sanofi alliance expansion brings $1B upfront and pipeline growth Sanofi will pay Regeneron $1 billion upfront plus up to $7 billion in milestones for four new antibodies, expanding the partnership that made Dupixent. This boosts Regeneron's cash and pipeline, but the deal left Dupixent profit-sharing unchanged, disappointing some investors and causing a 4% share drop.

    This is the period's biggest capital and pipeline event, directly affecting Regeneron's finances and investor sentiment.

  • Trevogrumab preserves muscle in Phase 2 obesity trial Regeneron's trevogrumab preserved about 70% of muscle loss caused by semaglutide in a Phase 2 trial. This opens a potential new obesity treatment, a large market, and shows Regeneron's research engine is producing promising results, which supports the stock.

    A positive clinical readout in a major new market area is a key driver of future growth expectations.

  • Kodiak eye drug matches Eylea with less frequent dosing Kodiak Sciences reported Phase 3 data showing its eye drugs matched Eylea's vision results with dosing every six months versus Eylea's eight weeks. This threatens Regeneron's key Eylea franchise, which is already facing biosimilar competition, and could pressure future sales.

    Eylea is a major revenue source, and new competition with better convenience could erode Regeneron's market share.

  • Pozelimab-cemdisiran highlighted as top emerging PNH therapy An analyst forecast named Regeneron's pozelimab plus cemdisiran as the emerging PNH therapy expected to generate the highest revenue, with Phase 3 results due late 2026 or early 2027. This supports hopes for a new blockbuster beyond current drugs.

    It points to a future growth driver and validates Regeneron's pipeline in a rare disease market.

▲3▼1

Regeneron's pipeline wins and Sanofi deal offset by Eylea competition

  • Sanofi alliance expansion brings $1B upfront and pipeline growth Sanofi will pay Regeneron $1 billion upfront plus up to $7 billion in milestones for four new antibodies, expanding the partnership that made Dupixent. This boosts Regeneron's cash and pipeline, but the deal left Dupixent profit-sharing unchanged, disappointing some investors and causing a 4% share drop.

    This is the period's biggest capital and pipeline event, directly affecting Regeneron's finances and investor sentiment.

  • Trevogrumab preserves muscle in Phase 2 obesity trial Regeneron's trevogrumab preserved about 70% of muscle loss caused by semaglutide in a Phase 2 trial. This opens a potential new obesity treatment, a large market, and shows Regeneron's research engine is producing promising results, which supports the stock.

    A positive clinical readout in a major new market area is a key driver of future growth expectations.

  • Kodiak eye drug matches Eylea with less frequent dosing Kodiak Sciences reported Phase 3 data showing its eye drugs matched Eylea's vision results with dosing every six months versus Eylea's eight weeks. This threatens Regeneron's key Eylea franchise, which is already facing biosimilar competition, and could pressure future sales.

    Eylea is a major revenue source, and new competition with better convenience could erode Regeneron's market share.

  • Pozelimab-cemdisiran highlighted as top emerging PNH therapy An analyst forecast named Regeneron's pozelimab plus cemdisiran as the emerging PNH therapy expected to generate the highest revenue, with Phase 3 results due late 2026 or early 2027. This supports hopes for a new blockbuster beyond current drugs.

    It points to a future growth driver and validates Regeneron's pipeline in a rare disease market.

▲3▼1

Regeneron beats on Dupixent/Eylea, wins rare-disease approval, faces lawsuit

  • Q2 beat on Dupixent and high-dose Eylea Regeneron beat second-quarter estimates: revenue rose 17% to $4.29 billion and adjusted profit was $14.29 a share. Dupixent sales jumped 38% to about $6 billion, and U.S. high-dose Eylea sales rose 52%. Strong demand for these key drugs lifts profit and supports the stock.

    This is the period's biggest positive fundamental driver of REGN's value.

  • Sanofi repayment improves margins Regeneron fully repaid the Sanofi Development Balance. An RBC analyst said this should improve margins and make second-half numbers look much better. Paying off this obligation frees up cash and boosts future profit, a positive for the stock.

    It is a concrete capital event that improves future profitability.

  • FDA approves Pasatru for rare FOP disease The FDA approved Pasatru (garetosmab) for fibrodysplasia ossificans progressiva, a rare bone disease, based on a Phase 3 trial showing 90% fewer new lesions. The patient group is tiny, so near-term sales are modest, but it proves Regeneron's drug platform still produces new approved medicines.

    A new FDA approval is a fresh product and pipeline milestone for REGN.

  • Securities class action over failed melanoma trial A securities class action alleges Regeneron misled investors about the Phase 3 Fianlimab-Libtayo melanoma trial, which failed its main goal and wiped out $11 billion in market value. The lead plaintiff deadline is September 14. Legal costs and uncertainty weigh on the stock.

    This is the main negative overhang on REGN this period.

July 2026
▼2▲1

Regeneron's pipeline setbacks trigger lawsuits, but cemdisiran advances

  • Cemdisiran regulatory progress FDA granted Priority Review and EMA accepted filings for cemdisiran in generalized myasthenia gravis. If approved, it would be the first siRNA treatment and only subcutaneous option dosed four times a year, opening a new revenue stream. FDA decision expected November 2026.

    This is a new positive regulatory catalyst that could drive future revenue and investor optimism.

  • Failed melanoma trial and securities lawsuits Regeneron faces multiple class action lawsuits alleging it misled investors about its Phase 3 Fianlimab-Libtayo melanoma trial, which failed to meet its primary endpoint. The trial failure wiped out $11 billion in market value, and the lawsuits create legal overhang and reputational risk.

    This is a new negative development that directly impacts Regeneron's stock through legal uncertainty and investor confidence.

  • Pipeline setbacks and mixed trial results Longleaf Partners Fund reported Regeneron was a Q2 detractor after disappointing trial results for a pipeline drug. The fund noted only one of three key pipeline readouts succeeded, below expectations. This highlights execution risk in Regeneron's drug development, weighing on sentiment.

    This new analyst commentary underscores pipeline challenges that could pressure the stock.

▼2▲1

Regeneron's pipeline setbacks trigger lawsuits, but cemdisiran advances

  • Cemdisiran regulatory progress FDA granted Priority Review and EMA accepted filings for cemdisiran in generalized myasthenia gravis. If approved, it would be the first siRNA treatment and only subcutaneous option dosed four times a year, opening a new revenue stream. FDA decision expected November 2026.

    This is a new positive regulatory catalyst that could drive future revenue and investor optimism.

  • Failed melanoma trial and securities lawsuits Regeneron faces multiple class action lawsuits alleging it misled investors about its Phase 3 Fianlimab-Libtayo melanoma trial, which failed to meet its primary endpoint. The trial failure wiped out $11 billion in market value, and the lawsuits create legal overhang and reputational risk.

    This is a new negative development that directly impacts Regeneron's stock through legal uncertainty and investor confidence.

  • Pipeline setbacks and mixed trial results Longleaf Partners Fund reported Regeneron was a Q2 detractor after disappointing trial results for a pipeline drug. The fund noted only one of three key pipeline readouts succeeded, below expectations. This highlights execution risk in Regeneron's drug development, weighing on sentiment.

    This new analyst commentary underscores pipeline challenges that could pressure the stock.

Q2 2026
▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

  • CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.

    This is a new deal that adds to Regeneron's pipeline and potential future earnings.

  • Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.

    Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.

  • FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.

    This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.

  • AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.

    This is a new competitive threat that could impact Regeneron's key product, Dupixent.

June 2026
▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

  • CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.

    This is a new deal that adds to Regeneron's pipeline and potential future earnings.

  • Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.

    Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.

  • FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.

    This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.

  • AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.

    This is a new competitive threat that could impact Regeneron's key product, Dupixent.

▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

  • CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.

    This is a new deal that adds to Regeneron's pipeline and potential future earnings.

  • Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.

    Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.

  • FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.

    This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.

  • AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.

    This is a new competitive threat that could impact Regeneron's key product, Dupixent.